This week, the FDA approved a vaccine for RSV that will be given to pregnant people to protect infants for the first six months of their lives. The news comes a few months ahead of cold and flu season, when RSV is typically at its worst.
More from Mom.com: What Is RSV?
Here's what we know so far
Yes, this vaccine has been tested
There was a clinical trial for Abrysvo that included approximately 7,400 participants. The most common side effects reported included fatigue, headache, injection at the site pain, muscle pain, nausea, joint pain, and diarrhea.
The drug was found to lower the risk of severe RSV in infants by 82% within about three months after birth. By around six months, it is still 69% effective.
"If brought into broad use, there will be children who otherwise would have been hospitalized, otherwise would have ended up on ventilators this winter, that won’t," Dr. Bill Gruber, senior vice president of clinical research and development for Pfizer, told NBC News.
